Drug Trial Radar · NCT06507839
Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268
Last checked: Nov 20, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
May 15, 2024
Primary completion
Nov 1, 2024
Study completion Nov 1, 2024
Sponsor
- Lead sponsor
- Thryv TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.
Conditions
- Atrial Fibrillation
Interventions
THRV-1268Drug
THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
PlaceboOther
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability: Number of Participants with Adverse EventsTime frame: SAD: Day 7; Food Effect: Day 15; MAD: Day 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.